- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Clinuvel Pharmaceuticals Ltd (CUV)
Clinuvel Pharmaceuticals Ltd stock price live, this page displays ASX CUV stock exchange data. View the CUV premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Clinuvel Pharmaceuticals Ltd real time stock price chart below.
What Is the Clinuvel Pharmaceuticals Ltd Stock Price Today?
The Clinuvel Pharmaceuticals Ltd stock price today is 9.23.
What Is the Stock Symbol for Clinuvel Pharmaceuticals Ltd?
The stock ticker symbol for Clinuvel Pharmaceuticals Ltd is CUV.
Is CUV the Same as $CUV?
$CUV is a common way to refer to the Clinuvel Pharmaceuticals Ltd ticker symbol in social media, forums, and online discussions. The dollar sign is a shorthand convention used to indicate that it is a stock ticker symbol
What Stock Exchange Does Clinuvel Pharmaceuticals Ltd Trade On?
Clinuvel Pharmaceuticals Ltd is listed and trades on the Sydney stock exchange.
Is Clinuvel Pharmaceuticals Ltd a Good Stock to Buy?
Determining whether Clinuvel Pharmaceuticals Ltd—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess the current Clinuvel Pharmaceuticals Ltd share price compared with the fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the CUV quote. (ISIN: AU000000CUV3)
What Is the Clinuvel Pharmaceuticals Ltd Stock Price Today?
The Clinuvel Pharmaceuticals Ltd stock price today is 9.23.
What Is the Stock Symbol for Clinuvel Pharmaceuticals Ltd?
The stock ticker symbol for Clinuvel Pharmaceuticals Ltd is CUV.
Is CUV the Same as $CUV?
$CUV is a common way to refer to the Clinuvel Pharmaceuticals Ltd ticker symbol in social media, forums, and online discussions. The dollar sign is a shorthand convention used to indicate that it is a stock ticker symbol
What Stock Exchange Does Clinuvel Pharmaceuticals Ltd Trade On?
Clinuvel Pharmaceuticals Ltd is listed and trades on the Sydney stock exchange.
Is Clinuvel Pharmaceuticals Ltd a Good Stock to Buy?
Determining whether Clinuvel Pharmaceuticals Ltd—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess the current Clinuvel Pharmaceuticals Ltd share price compared with the fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the CUV quote. (ISIN: AU000000CUV3)
9.23
+0.09(+0.98%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
9.16
9.37
52 wk Range
8.91
14.00
CUV is included in our AI-picked strategies. See how they work
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
9.169.37
52 wk Range
8.9114.00
Key Statistics
Edit
Prev. Close
Open
Volume
Average Vol. (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(0.55%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Vol. (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(0.55%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
CUV Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
23.38
Upside
+153.35%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Impressive gross profit margins
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Sell
Moving Averages
Neutral
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company’s pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. It is also developing NEURACTHEL (ACTH), an adrenocorticotropic hormone for targeting neurological, endocrinological, and degenerative disorders; and pharmaceutical formulations melanocortin technology for the treatment of a range of disorders. In addition, the company provides photocosmetic products for individuals and populations at risk of exposure to ultraviolet and high energy visible light, and in need of assistance in DNA repair and melanogenesis of the skin. The company was incorporated in 1999 and is headquartered in Melbourne, Australia.
Clinuvel Pharmaceuticals Ltd Earnings Call Summary for H1/2026
- Clinuvel reported 4% revenue growth to AUD 36.8M in H1 2026, the highest first-half sales ever, but stock fell 3.24% to AUD 11.41.
- Expenses surged 22% due to strategic expansion and regulatory costs, pressuring net profit despite 20th consecutive profitable period.
- Company remains debt-free with AUD 233M cash reserves, up AUD 9M, supporting Singapore research facility expansion over five years.
- FY2026 guidance shows EPS forecast of -0.07 USD with revenue projected at USD 54.76M, down slightly from FY2025's USD 55.04M forecast.
- Management emphasizes long-term growth strategy despite short-term profitability impact, leveraging strong balance sheet for expansion initiatives.
Last Updated: 02/26/2026, 06:00 AM
Read Full TranscriptClinuvel Pharmaceuticals investor slides for H1/2026
Last Update: Feb 26, 2026
See full investor slides
Compare CUV to Peers and Sector
Metrics to compare | CUV | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCUVPeersSector | |
|---|---|---|---|---|
P/E Ratio | 14.4x | −0.7x | −0.5x | |
PEG Ratio | −0.87 | 0.01 | 0.00 | |
Price / Book | 1.9x | 2.5x | 2.6x | |
Price / LTM Sales | 4.9x | 3.4x | 3.2x | |
Upside (Analyst Target) | 137.3% | 46.7% | 45.7% | |
Fair Value Upside | Unlock | 7.8% | 4.8% | Unlock |
Analyst Ratings
8 Buy
0 Hold
0 Sell
Ratings:
8 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 23.38
(+153.35% Upside)
Earnings
Latest Release
Feb 25, 2026
EPS / Forecast
0.21 / 32.40
Revenue / Forecast
36.93M / 40M
People Also Watch
FAQ
What Is the Clinuvel Pharmaceuticals (CUV) Stock Price Today?
The Clinuvel Pharmaceuticals stock price today is 9.23 AUD.
What Stock Exchange Does Clinuvel Pharmaceuticals Trade On?
Clinuvel Pharmaceuticals is listed and trades on the Sydney Stock Exchange.
What Is the Stock Symbol for Clinuvel Pharmaceuticals?
The stock symbol for Clinuvel Pharmaceuticals is "CUV."
Does Clinuvel Pharmaceuticals Pay Dividends? What’s The Current Dividend Yield?
The Clinuvel Pharmaceuticals dividend yield is 0.55%.
What Is the Clinuvel Pharmaceuticals Market Cap?
As of today, Clinuvel Pharmaceuticals market cap is 463.85M AUD.
What Is Clinuvel Pharmaceuticals's Earnings Per Share (TTM)?
The Clinuvel Pharmaceuticals EPS (TTM) is 0.64.
From a Technical Analysis Perspective, Is CUV a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Clinuvel Pharmaceuticals Stock Split?
Clinuvel Pharmaceuticals has split 2 times.
How Many Employees Does Clinuvel Pharmaceuticals Have?
Clinuvel Pharmaceuticals has 16 employees.
What is the current trading status of Clinuvel Pharmaceuticals (CUV)?
As of Apr 16, 2026, Clinuvel Pharmaceuticals (CUV) is trading at a price of 9.23 AUD, with a previous close of 9.14 AUD. The stock has fluctuated within a day range of 9.16 AUD to 9.37 AUD, while its 52-week range spans from 8.91 AUD to 14.00 AUD.
What Is Clinuvel Pharmaceuticals (CUV) Price Target According to Analysts?
The average 12-month price target for Clinuvel Pharmaceuticals is 23.38 AUD, with a high estimate of 40.5 AUD and a low estimate of 13 AUD. 8 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +153.35% Upside potential.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.